Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07568015 · ClinicalTrials.gov registry record · NA
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
A NA study, sponsored by Brixton Biosciences.
- Not yet
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07568015 is a NA study that has not yet begun recruiting, run by Brixton Biosciences. The registered enrollment target is 100 participants.
The verdict
NCT07568015, a NA study, has not yet begun recruiting, sponsored by Brixton Biosciences.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.
Interventions
- DRUG Triamcinolone acetate
- DEVICE ReneuRx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2029-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07568015
The ClinicalTrials.gov registry entry for NCT07568015 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brixton Biosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone acetate is the first listed.
NCT07568015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07568015 about?
NCT07568015 is a clinical study titled "ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain". The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study vi...
What is the current status of trial NCT07568015?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-07-01. Estimated completion is 2029-11-01.
What interventions are being tested in trial NCT07568015?
The interventions under investigation include: Triamcinolone acetate (DRUG), ReneuRx (DEVICE).
Who is sponsoring clinical trial NCT07568015?
This trial is sponsored by Brixton Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.